FUNDAMENTALS
EdgeFII/DII
ALKEMAlkem Laboratories
₹5,185.00+0.78%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
ALKEMNSE · EquityPharmaceuticals

Alkem Laboratories

ISIN
INE540L01014
Instrument key
NSE_EQ|INE540L01014
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹5,185.00+40.00 · +0.78%
Day rangecircuit ₹4,666.50 – ₹5,703.50
5,114.00
5,185.00

as of 21/11/2026, 3:37:36 pm

Open
₹5,154.50
Day high
₹5,185.00
Day low
₹5,114.00
Prev. close
₹5,145.00
Volume
69.6K
VWAP
₹5,155.25

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 month · 30-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 1M
+5.26%
4,926.00 → 5,185.00
Period high
₹5,475.00
9/11/2026
Period low
₹4,811.00
22/10/2026
From high
-5.30%
+7.77% from low
Avg volume
12.1K
33.46 L total
Candles
276
133 up / 139 down
20 Nov 2026O 5,166.50H 5,185.00L 5,166.50C 5,185.00Vol 1.0K
SMA 20SMA 50Averages need 50 candles before they begin
Candle data276 rows of open, high, low, close and volumeShowHide
20 Nov 20265,166.505,185.005,166.505,185.00+0.36%18.501.0K
20 Nov 20265,163.005,174.505,158.005,166.50+0.07%16.5010.3K
20 Nov 20265,168.005,168.505,150.005,164.00-0.08%18.508.7K
20 Nov 20265,173.005,173.005,154.505,168.00-0.10%18.503.5K
20 Nov 20265,171.005,174.005,168.005,170.00-0.02%6.003.2K
20 Nov 20265,164.005,174.505,163.005,172.00+0.15%11.502.5K
20 Nov 20265,162.005,166.005,158.005,163.50+0.03%8.002.3K
20 Nov 20265,155.005,172.505,151.505,164.00+0.17%21.004.0K
20 Nov 20265,155.005,160.505,149.005,155.000.00%11.507.4K
20 Nov 20265,154.505,157.005,143.505,153.50-0.02%13.503.7K

Historical price and volume data · Showing 1–10 of 276

1 / 28

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

29.54
Company
29.54
Sector
-45.02

Worse than sector by 166%

P/B

Price ÷ book value per share

4.16
Company
4.16
Sector
4.21

Better than sector by 1%

ROA

Net income ÷ total assets

9.08%
Company
9.08%
Sector
1.19%

Better than sector by 663%

ROE

Net income ÷ shareholders' equity

13.91%
Company
13.91%
Sector
-0.4%

Better than sector by 3578%

ROCE

EBIT ÷ capital employed

17.87%
Company
17.87%
Sector
15.44%

Better than sector by 16%

Quick Ratio

Liquid assets ÷ current liabilities

1.86
Company
1.86
Sector
4.8

Worse than sector by 61%

EV/EBITDA

Enterprise value ÷ EBITDA

17.49
Company
17.49
Sector
22.86

Better than sector by 23%

04/Business

About the company

Sector: Pharmaceuticals

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.

Sector market cap (INR)
₹61,799 Cr

reported in crore

Sector market cap (USD)
$6.87B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹4,686 Cr
+20.38% vs Jun 2026
Net profit · Sep 2026
₹668 Cr
+28.04% vs Jun 2026
Operating margin
21.3%
was 19.8%
Revenue CAGR · 4p
6.5%
profit 0.7% · op 8.6%
Filed order
Revenue4,6863,8933,8033,880
Revenue growthreported20.4%2.4%-2.0%—
Operating profit1,000772423781
Operating profit growthreported29.5%82.6%-45.9%—
Operating marginderived21.3%19.8%11.1%20.1%
Net profit668521252654
Net profit growthreported28.0%107.2%-61.5%—
Net marginderived14.2%13.4%6.6%16.8%
EPS — basic₹/share, annual——192.51—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue14,71212,96512,66811,599
Other Income583494311216
Total Revenue15,29613,45812,97811,815
Total Expenses12,25010,93110,83410,408
Profit Before Tax2,8712,5272,0231,305
Tax518311212298
Profit After Tax2,3532,2161,8111,007
EPS - Basic192.51181.11150.1982.31
EPS - Diluted192.51181.11150.1982.31

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹20,873 Cr
+17.99% YoY
Total liabilities
₹6,524 Cr
Net worth
₹14,349 Cr
Liabilities ÷ assets
31.3%
lower means a lighter balance sheet
Filed order
Total assets20,87317,69115,57513,757
Total liabilities6,5245,2574,8614,322
Net worthderived14,34912,43410,7149,435
Liabilities ÷ assetsderived31.3%29.7%31.2%31.4%
Asset growthderived18.0%13.6%13.2%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets8,6626,8805,1635,027
Current Assets12,21110,81110,4128,730
Total Assets20,87317,69115,57513,757
Current Liabilities4,7833,9613,9953,707
Net Current Asset7,4286,8516,4175,023
Non-Current Liabilities1,7411,297866615
Equity Capital14,34912,43410,7149,435
Total Equity & Liabilities20,87317,69115,57513,757

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹1,963 Cr
+2.62% YoY
Investing
-₹1,667 Cr
Financing
-₹503 Cr
Free cash flow
₹296 Cr
operating + investing
Filed order
Operating activities1,9631,9131,9481,683
Operating changereported2.6%-1.8%15.8%—
Investing activities-1,667-1,299-1,008113
Investing changereported-28.4%-28.8%-993.7%—
Financing activities-503-811-1,145-1,761
Financing changereported37.9%29.2%35.0%—
Net cash flowderived-208-197-20535
Free cash flowoperating + investing2966149401,795

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax2,8712,5272,0231,305
Income before WC changes3,0072,6312,4071,629
Change in Assets-664-455-430262
Change in Liabilities24924137965
Change in WC-415-214-52327
Cash flow from Operations1,9631,9131,9481,683
Cash flow from Investing-1,667-1,299-1,008113
Cash flow from Financing-503-811-1,145-1,761
Total Cash Flow-208-197-20535
Cash (Start of the year)-12066274232
Cash (End of the year)-342-12066274

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
49.70%
0.00 pts QoQ
FII
10.32%
-0.10 pts QoQ
DII (other)
5.04%
-0.89 pts QoQ
Mutual funds
17.79%
+1.08 pts QoQ
Retail & others
17.15%
-0.10 pts QoQ
Filed order
Promoters49.7%49.7%51.2%51.2%
FII10.3%10.4%10.2%10.0%
DII (other)5.0%5.9%5.8%5.5%
Mutual funds17.8%16.7%15.6%16.1%
Retail & others17.1%17.3%17.3%17.3%
Promoters — QoQ changepts, derived0.0%-1.5%0.0%—
FII — QoQ changepts, derived-0.1%0.3%0.2%—
DII (other) — QoQ changepts, derived-0.9%0.1%0.3%—
Mutual funds — QoQ changepts, derived1.1%1.1%-0.5%—
Retail & others — QoQ changepts, derived-0.1%0.0%-0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹10.00500.0%07 Aug 202607 Aug 202629 May 2026
DividendInterim₹43.002150.0%20 Feb 202620 Feb 202613 Feb 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

5102050
  • Thumbnail: Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility
    2d ago19/11/2026, 2:07:35 pm
    Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility

    Alkem Labs stated that it continues to manufacture and supply approved products from the said facility to the US market, adding that there is no material impact on current operations, financial, or other activities of the company.

  • Thumbnail: Groww shares worth ₹1,905 crore changes hands in block deal; Alkem Labs sees trade worth ₹300 crore
    4d ago17/11/2026, 9:31:34 pm
    Groww shares worth ₹1,905 crore changes hands in block deal; Alkem Labs sees trade worth ₹300 crore

    On Tuesday, venture capital firm Ribbit Capital’s investment entities, Ribbit Capital V and Ribbit Cayman GW Holdings V Ltd, sold a total of 8.7 crore shares of Groww for ₹1,905.3 crore.

Showing 1–2 of 2 articles